MC-Val-Cit-PAB-VX765

• CAT Number: I007925
• CAS Number: N/A
• Molecular Formula: C53H71ClN10O14
• Molecular Weight: 1107.657
• Purity: ≥95%
• Synonyms: MC-Val-Cit-PAB-VX765; MC-Val-Cit-PABC-VX765; Belnacasan-conjugate; VX765-conjugate.;4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (2-chloro-4-(((S)-1-((S)-2-(((2R,3S)-2-ethoxy-5-ox
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• SMILES: O=C1C=CC(N1CCCCCC(N[C@H](C(N[C@@H](CCCNC(N)=O)C(NC2=CC=C(COC(NC3=CC=C(C(N[C@H](C(N4CCC[C@H]4C(N[C@@H]5[C@H](OCC)OC(C5)=O)=O)=O)C(C)(C)C)=O)C=C3Cl)=O)C=C2)=O)=O)C(C)C)=O)=O

MC-Val-Cit-PAB-VX765 (Cat No.: I007925) is a prodrug designed for targeted delivery in cancer therapy. It consists of a peptide linker, MC-Val-Cit, attached to the VX765 molecule, which is an inhibitor of the enzyme caspase-1. By inhibiting caspase-1, VX765 can modulate inflammation and pyroptosis, both of which play a role in cancer progression. The prodrug form, MC-Val-Cit-PAB, ensures selective activation in tumor tissues, improving the efficacy and reducing off-target effects, making it a promising candidate for cancer treatment.